| Company/Division name | Xellia Pharmaceuticals |
| Parent company | Novo Holdings A/S |
| Type of work | Manufacturing |
| If manufacturing, is the company a contract manufacturer? | Yes |
| Reshoring category: | Foreign Direct Investment |
| Total number of jobs (added or to be added): | 300 |
| Year reshoring announced: | 2015 |
| Year reshoring implemented or to be implemented: | 2021 |
| Capital investment ($): | 200 |
| Country(ies) from which reshored: | Denmark |
| City reshored to: | Cleveland |
| State(s) reshored to: | OH |
| If relevant, work nearshored to: | - |
| Industry(ies): | Chemicals |
| Product(s) reshored | lyophilized vancomycin, sterile injectables |
| What domestic positive factors made reshoring more attractive? | Proximity to customers/market, Other, Covid-19 |
